BUDGET IMPACT ANALYSIS OF TREATMENT WITH ULTIBRO BREEZHALER® VERSUS SERETIDE DISKUS® 50/500 ΜG FOR MODERATE TO VERY SEVERE COPD PATIENTS
Author(s)
Mahieu N, Decuypere L, Le gros V, Le vagueresse M, Cariou C, Duteil E, Duco J
Novartis Pharma, Rueil-Malmaison, France
OBJECTIVES: To assess the budget impact of COPD management with Ultibro Breezhaler® (UB) vs. Seretide Diskus® METHODS: A budget impact model was developed to estimate healthcare savings of a broader use of UB vs. SD in the treatment of patients with moderate to very severe COPD (25% ≤ post bronchodilator FEV1 < 60%), who had at least one exacerbation in the previous year and an mMRC≥2. Pneumonia (severe and non-severe) and exacerbations (moderate and severe) rates from the 52-weeks-duration FLAME study were used. The model used management costs (€, 2016) of COPD (treatments, management of exacerbations and pneumonia). For each stay, a DRG cost (€, 2014) was calculated. No discount rate was applied. RESULTS: The mean cost of treatment combined with the impact of exacerbations and the management of adverse events decreased by 137€ per patient per year (1405€ with SD vs. 1268€ with UB). Based on French guidelines (SPLF, 2016), we estimated that 250 000 patients needed a 2nd line of treatment for the prevention of exacerbations among 2.5 millions of COPD patients in France. A linear growth of UB market shares for these patients from 8% (actual) to 50%, for instance, would allow to save 70M€ (cumulated) for French NHS over the next 6 years. Currently, French NHS spends 3.5 billions euros every year for the management of COPD in France. CONCLUSIONS: From the French NHS perspective, replacing SD by UB in the COPD treatment strategy of patients with moderate to very severe COPD who had at least an exacerbation in the previous year with an mMRC≥2 could generate substantial savings.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRS69
Topic
Health Policy & Regulatory, Health Service Delivery & Process of Care
Topic Subcategory
Hospital and Clinical Practices, Reimbursement & Access Policy
Disease
Respiratory-Related Disorders